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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.004Pancreatic ductal adenocarcinoma, one of the most feared lethal and painful diseases, is increasing in
incidence. The poor prognosis of pancreatic ductal adenocarcinomaeaffected patients primarily is owing
to our inability to develop effective therapies. Mechanistic studies of genetic, epigenetic, and cell-to-cell
signaling events are providing clues to molecular pathways that can be targeted in an attempt to cure this
disease. The current review article seeks to draw inferences from available mechanistic knowledge to build
a theoretical framework that can facilitate these approaches. This conceptual model considers pancreatic
cancer as a tissue disease rather than an isolated epithelial cell problem, which develops and progresses in
large part as a result of three positive feedback loops: i) genetic and epigenetic changes in epithelial cells
modulate their interaction with mesenchymal cells to generate a dynamically changing process of
abnormal histogenesis, which drives more changes; ii) the faulty tissue architecture of neoplastic lesions
results in unsynchronized secretion of signalingmolecules by cells, which generates an environment that is
poor in oxygen and nutrients; and iii) the increased metabolic needs of rapidly dividing cells serve as an
evolutionary pressure for them to adapt to this adverse microenvironment, leading to the emergence of
resistant clones. We discuss how these concepts can guidemechanistic studies, as well as aid in the design
of novel experimental therapeutics. (Am J Pathol 2013, 182: 1078e1086; http://dx.doi.org/10.1016/
j.ajpath.2012.12.004)Supported by grants from Ligue Contre le Cancer, INSERM, and INCA
(Institute National du Cancer) (J.L.I.); the NIH (DK52913), the Mayo
Clinic Center for Cell Signaling in Gastroenterology (P30DK084567), and
the Translational Epigenomic Program, Center for Individualized Medicine,
Mayo Clinic (R.U.); and by the Mayo Clinic SPORE in Pancreatic Cancer
(P50 CA102701 and CA136526 to M.E.F.-Z.).The incidence of pancreatic ductal adenocarcinoma (PDAC)
is increasing with more than 44,000 predicted new cases in the
United States and 65,000 in Europe,1,2 with a 5-year survival
of less than 5%. PDAC arises from epithelial cells through
an accumulation of genetic and epigenetic alterations in
oncogenes and tumor suppressors,3,4 which contribute to
form precursor lesions5,6 known as pancreatic intraepithelial
neoplasias (PanINs) (Figures 1 and 2). Less frequently, PDAC
may progress from two types of cystic lesions:mucinous cysticstigative Pathology.
.neoplasms and intraductal papillary mucinous neoplasms. In
this process, tumor cells proliferate and secrete molecules that
drive their communication with surrounding cells. In the
Figure 1 Self-reinforcing processes that drive abnormal histogenesis during the development of pancreatic cancer. Diagrammatic representation of
positive feedback loops that contribute to pancreatic carcinogenesis involves the progressive genetic and epigenetic changes in epithelial cells, which
modulate their interaction with mesenchymal cells to generate a dynamically changing process of abnormal histogenesis to further drive more changes. The
faulty tissue architecture of neoplastic lesions results in unsynchronized secretion of signaling molecules by cells, which generates an oxygen- and nutrient-
poor environment as a result of aberrant angiogenesis. Finally, the increased metabolic needs of rapidly dividing cells serve as an evolutionary pressure for
them to adapt to this adverse microenvironment, leading to the emergence of resistant clones.
Abnormal Histogenesisfashion of a self-reinforcing loop, surrounding cells also
proliferate and secrete new substances, which initiate new
communications among themselves, with other noncancer cell
types within the tumor (Figure 3).
This extended cellular network generates a dynamic tumor
microenvironment that inﬂuences genetically heterogeneousFigure 2 Histologic correlates of abnormal histogenesis during pancreatic ca
genic animals were stained using the Masson trichromic method, in which epitheli
series of micrographs show that from the beginning, pancreatic cancer developmen
mesenchyma. A: PanIN1A lesion formed by cells with normal-shaped nuclei but
lesion showing papillary projections formed by cells with normal-looking nuclei w
lesion. C: PanIN2 lesion with abnormally shaped nuclei and typical papilar projec
piling up of nuclei with incipient atypia showing anisokaryosis, poikilokaryosis, an
duct-like structure. E: PanIN3 lesion with extensive atypia showing the surround
cancerous lesions embedded in a dense desmoplasia.
The American Journal of Pathology - ajp.amjpathol.orgtumor cells and selects for highly proliferative and resistant
clones. Epithelial and mesenchymal cells each contribute to
remodeling the stroma into a dense ﬁbrotic tissue (desmo-
plasia) enriched in ﬁbrillar collagens, stromal cells, and other
migratory cell populations. Accordingly, each component of
the developing tumor takes an active role in the process ofncer progression. Neoplastic pancreatic tissue from p48-cre/KrasG12D trans-
al cells are labeled in red and the extracellular matrix is labeled in blue. This
t involves the tight interaction between epithelial cells and its surrounding
showing incipient nuclear piling up and increased cytoplasm. B: PanIN1B
ith a mucin-containing cytoplasm that displaces nuclei to the base of the
tions occupying the duct lumen. D: PanIN2 to 3 lesion showing the typical
d papilar projections. Note that a ring of extracellular matrix surrounds the
ing ECM as a dense ring that deforms the ductular structures. F: Multifocal
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Figure 3 Epithelialemesenchymal interactions
during the development of pancreatic cancer. The
functional co-evolution between pancreatic epithelial
cells and their stromal counterparts from early pre-
neoplastic to frank neoplastic lesions is shown.
Several growth factors are secreted at abnormal
amounts, times, and places to generate abnormal
signaling cascades that drive the communication
between both the epithelial compartment and the
tissue microenvironment. As explained in the text,
different growth factors exert their function either in
a paracrine or autocrine manner to help form the
tumors, desmoplasia, and generate an oxygen- and
nutrient-poor tumor bed, impacting the pathobiology
of pancreatic cancer and contributing to its resistance
and aggressiveness. FGF, ﬁbroblast growth factor;
MMP, matrix metalloproteinase; PDGF, platelet-
derived growth factor; SDF1, serum derived factor-1;
SHH, Sonic hedgehog; VEGF, vascular endothelial
growth factor.
Iovanna et alcarcinogenesis. Thus, dissecting the temporal and spatial
sequence of events that drives these processes should provide
new ways for therapeutically transforming pancreatic cancer
from a rapidly fatal to a chronic and treatable, or even curable,
disease.
Stromal Cells Are Key Players in Pancreatic
Cancer Development
The stroma co-evolving with tumor cells during PDAC
progression is composed of several cell types,7e9 including
ﬁbroblasts, pancreatic stellate cells (PSCs), endothelial cells,
bone marrowederived cells, as well as inﬂammatory and
immunoregulatory populations. Although ﬁbroblasts con-
tribute to pancreatic ﬁbrosis, PSCs also contribute to this
process by secreting ﬁbrillary collagens (type 1, type 3) and
ﬁbronectin.10 PSCs are located between acini and endothelial
cells, where they inﬂuence the differentiation and function of
acinar cells or work as pericytes. PSCs represent less than 5%
of cells within the normal gland10 but in tumors they prolif-
erate to outnumber malignant epithelial cells.
These cells normally exist in a quiescent state marked by
the presence of vitamin Aerich lipid droplets, desmin, and
glial-ﬁbrillary-acidic protein. On tissue stress and injury,
PSCs become activated myoﬁbroblast-like cells, lose their
droplets, express a-smooth muscle actin, and secrete extra-
cellular matrix (ECM) proteins.8,11 The proliferation of these
a-smooth muscle actinepositive cells and the deposition of
collagen in human PanIN and PDAC compared with normal
pancreas is observed clearly in micrographs of human patient
samples and mice models. The idea that activated myoﬁ-
broblasts in the pancreas arise from PSCs has many propo-
nents but still remains under debate12 because a few studies
suggest that they can originate from circulating bone mar-
rowederived stem cells.13,14 Nevertheless, the currently
available data make it impossible to ignore the fact that
stromal cells, both resident and migratory, are as important as1080epithelial cancer cells in the formation and pathobiology of
PDAC tumors.
Epithelial and Mesenchymal Interactions Are
Critical in the Histogenesis of PanINs
Even at the PanIN stage, abnormal epithelial cells exert inﬂu-
ence on their surrounding microenvironment. PSCs are found
within PanINs from human pancreatic samples and mouse
models15,16 where they are stimulated by signals from other
cells, including epithelial populations17,18(Figures 1 and 3).
These signals include platelet-derived growth factor, ﬁbro-
blast growth factor, and transforming growth factor b1
(TGF-b1). TGF-b stimulates collagen I, collagen III, and
ﬁbronectin biosynthesis, whereasﬁbroblast growth factor and
platelet-derived growth factor induce PSC proliferation.17e19
When orthotopically injected into mouse pancreata, TGF-
b1eoverexpressing PDAC cells20 increase desmoplasia,
showing that secreted factors from epithelial cells can induce
the mesenchymal reaction characteristic of pancreatic cancer.
Sonic hedgehog, which is expressed during development and
silenced in mature cells, becomes re-expressed again in
PanINs, increasing in concentration during the progression of
PanIN2 and 3 to PDACs.21 Expression of Sonic hedgehog in
mice using the pdx1 promoter leads to PanIN formation.21 In
contrast, elastase 1edriven expression of this factor in
pancreatic acinar cells does not result in PDAC but causes an
expansion of nestin-positive mesenchymal cells.22 Together,
these studies provide relevant examples of how communi-
cation between both malignant epithelial cells and their
nonmalignant mesenchymal counterparts are established de
novo and aid the progression from a preneoplastic into a frank
neoplastic phenotype.
Other stromal responses include the effect of angiogenic
factors secreted by tumor cells that act on inﬂammatory
cells.23e26 In exchange, these inﬂammatory cells trigger
a reinforcing positive feedback loop by producing IL-6, thusajp.amjpathol.org - The American Journal of Pathology
Abnormal Histogenesisinducing proliferation of premalignant cells and their
protection from apoptosis.27 These protumoral effects are
synergized by granulocyte-macrophage colony-stimulating
factor,28 which is produced by both murine and human PanIN
cells.28 Granulocytes, mast cells, and macrophages located
within human PDAC produce late protumoral factors, such as
TGF-b29 and vascular endothelial growth factor. Therefore,
an intense exchange of information between tumor cells,
stromal cells, and immune cells contribute to arm PDACwith
its aggressive nature.30 Interestingly, however, few studies
directly have investigated whether stromal cells from PanINs
secrete growth factors and cytokines. Serum-derived factor-1
is secreted by PSCs from both human and mouse PanINs,
although the receptor for this factor, CXCR4, is expressed
in PanINs and cancer epithelial cells.31e33 Thus, mesen-
chymal serum-derived factor-1 stimulates CXCR4 on PDAC
cancer cells, leading to signals that promote their survival,
proliferation, and migration.32e34 Combined, this knowledge
supports the conclusion that paracrine signaling from PSCs to
PDAC cells stimulates the malignancy of PDAC cells
beginning at the PanIN stage.
In this regard, complementary in vitro studies allow us to
draw mechanistic information that explains the behavior of
stromal cells at the PanIN stage. Conditioned media from
PSCs, for instance, stimulates tumor cell proliferation and
migration.31,35,36When co-injected into nudemice, PSCs also
mediate protumoral effects on epithelial cells through the
secretion of epidermal growth factor, platelet-derived growth
factor, and ﬁbroblast growth factor, whereas other factors
such as TGF-b1, IL-1, and IL-6 act in an autocrine manner to
exacerbate PSC activation.37,38 Activated PSCs produce
several types of collagen9,39 and diffusible ECM components
that also help to stimulate PDAC cell proliferation and
migration.40e42 However, this desmoplasia is not homoge-
neous in composition, which likely affects PanINs differently
depending on whether they are located near areas of densely
packed ﬁbers or juxtaposed to looser tissue layers. This
heterogeneously remodeled ECM results from the localized
secretion of powerful proteolytic machinery. Matrix metal-
loproteinases, the best-studied ECM proteases, are secreted
by many cells from the tumor, including PSCs, tumor
epithelial cells, and leukocytes, to both degrade ﬁbers and
release growth factors sequestered in the ECM.43
All these studies revealed an exquisite communication
network that mediates reciprocal signals among most cells
within the tumor as well as messages going from cells to the
ECMandback.Suchﬁndingsguide us to the idea that drugs that
inhibit stromal cell activation or stromal/tumor cell communi-
cation may have promising therapeutic value in PDAC.Exploring the Concept of PDAC as a Disease of
Abnormal Tissue Morphogenesis
One of the striking characteristics of cancer is the tendency to
recapitulate, in part, the morphologic features of the organThe American Journal of Pathology - ajp.amjpathol.orgfrom which they originate. In many cases, these features are
pathognomonic so that a well-trained pathologist can predict
the site of a primary tumor by looking at a metastasis. The fact
that cancers do not display an unlimited variety of histologic
proﬁles but rather present with similar phenotypes indicates
that our genes and the epigenome, which regulates their
temporal and spatial pattern of expression, not only give rise
to the normal phenotype, but also shape its neoplastic coun-
terpart. This idea is supported by the fact that pancreatic
epithelial cells display characteristics of progenitor pop-
ulations found in early development of pluripotent stem cells
with similar features to those described in other forms of
cancer.44e46 For example, a number of signaling pathways
(eg, hedgehog, Notch, and Wnt) and transcription factors
(eg, Gata4, Nanog) associated with embryonic development
are expressed in cancer cells.47e50 Cooperation between
pancreatic tumors and surrounding tissue that leads to unde-
sirable outcomes such as hypoxia and chemoresistance can be
seen as resulting in part from a faulty morphogenetic cascade
that tries but fails to recapitulate normal histogenesis.
During normal development, a precise series of gene
expression events generate signals (eg, angiogenic factor) and
outcomes (eg, angiogenesis) in a controlled manner at the
appropriate level, place, and time. In contrast, during carci-
nogenesis, many molecules are produced simultaneously,
leading to confusing morphogenic instructions that prevent
normal programs from occurring or, if they do occur, they
begin and terminate at the wrong time and place. This lack of
synchronization of morphogenetic cascades gives rise to
a distorted architecture, which causes epithelial and mesen-
chymal cells to miscommunicate. Thus, once abnormal
morphogenesis has begun, it causes additional architectural
problems, behaving as another of the self-reinforcing mech-
anisms that are critical to the formation of PDAC. Numerous
studies have shown the re-emergence of mesenchymal/
epithelial developmental signaling pathways in PDAC. Early
in development, for instance, hedgehog is absent from the
dorsal and ventral pancreatic endoderm,51 but its forced
expression in this tissue inﬂuences the stroma.51 Sonic
hedgehog expression in PDAC cells also stimulates the
formation and remodeling of the tumor microenvironment in
a manner that is abnormal. Thus, HH expression in PDAC
may be thought of as a faulty recapitulation of an early
developmental program of tissue morphogenesis. Similar
examples are foundwithﬁbroblast growth factors 1, 7, and 10,
serum-derived factor-1, and many members of the TGF-b/
activin/nodal/inhibin family of cytokines. Thus, together, this
knowledge serves as evidence that PDAC presents as
a process of histogenesis that progresses abnormally as
a result of signals arising and terminating inappropriately.
This concept is worthy of being compared and contrasted
with previous theories of carcinogenesis. Indeed, until the
1970s, most informed investigators agreed that pancreatic
cancer recapitulated developmental programs, and in that
sense our considerations are not new. However, most of these
early theories viewed neoplastic lesions as arising from1081
Iovanna et aldedifferentiated cells, but current considerations in this
regard are different because dedifferentiated cells imply that
an adult population has reverted its phenotype to that found in
an early developmental stage. If that was the case, neoplastic
cells would have all of the instructions necessary for not only
initiating the formation, but also the completion, of an organ,
develop normal architectural relationships within the organ,
organize an efﬁcient system of nutrient supply (vessels), and
appropriate disposal of its products (secretory ducts). In
addition, their genes would lack mutations and be expressed
in a sequential manner as needed. Obviously, this is not the
case with pancreatic cancer, leading some investigators to
alternatively propose that PDAC arises through a process of
transdifferentiation. Examples of this phenomenon in the
pancreas are found in benign intraductal papillary mucinous
neoplasms where the normal ductular cells transdifferentiate
into those resembling the gastrointestinal epithelium. Inter-
estingly, this type of differentiation also has been proposed
for pancreatic ductal adenocarcinoma, primarily based on
studies in animal models, although the evidence supporting
transdifferentiation in human PDAC still remains contro-
versial. Other investigators have invoked abnormal differ-
entiation of stem cells as the origin for this type of cancer. It is
noteworthy, however, that what we call stem cells in solid
tumor are different from those found in embryonic devel-
opment with a differentiation potential, which is currently
unclear.
Thus, these considerations lead us to propose that
pancreatic cancer cells neither go back in differentiation nor
do they cross the differentiation barrier to another cell type.
Rather, pancreatic cancer cells appear to have their own
differentiation pathway, which in most part uses over-
lapping gene networks with those turned on and off during
development to produce structures that are phenotypically
similar yet distinct from those found in embryonic devel-
opment. In this context, we suggest that this neoplasia
develops as a sui generis case of abnormal morphogenesis.
This inference should help to develop a holistic view of the
disease as a process in which unsynchronized molecular and
cellular events taking place in most of the structures that
form the tumor, and not exclusively in the epithelial cells,
self-reinforce a path toward progression. When, where, and
how to intervene with these processes, although a signiﬁcant
challenge, should be aided by the conceptual framework
discussed in this article.
Angiogenesis, Hypoxia, and Nutrient
Deprivation Behave as a Positive Feedback
Loop Driving the Selection of Cells with High
Malignant Potential
Abnormal architectural relationships among structures
forming a deﬁned tissue are one of the most obvious conse-
quences of abnormal morphogenesis either during normal
development (eg, thalidomide toxicity) or in cancer. In this1082section, we discuss how an increased demand of nutrients and
oxygen by cells from the PDAC tumor bed is met by a relative
decrease in their supply imposed by both architectural and
functional changes that occur during the remodeling of pre-
neoplastic lesions as they becomemalignant. In particular, we
recognize that a faulty architectural design results in another
positive feedback loop that leads to the establishment of more
aberrant structures. The law of supply and demand, imposed
by a decrease in the offering of nutrients and an increase in
energetic needs by the pancreatic cancer, lends itself as a good
example of this positive feedback loop. Indeed, by the time
PDAC is diagnosed, most patients have invasive tumors with
extensive desmoplasia, which are unexpectedly hypovascu-
larized52,53 and poorly perfused, thereby generating low
oxygen and nutrient availability at tumor sites. Reduced
vascularity also is found in chronic pancreatitis, suggesting
that hypoxic conditions begin early during the development of
PDAC and only increase in frank adenocarcinoma.54 These
features, along with the increased metabolic needs of rapidly
proliferating cells, function as a selection pressure toward
their adaption to conditions that would be suboptimal to
normal cells, thus promoting tumor cell survival and their
characteristic resistance to chemotherapy.55Hypoxia Plays a Pivotal Role in the Selection of
Aggressive Pancreatic Cancer Cell Clones
The effect of hypoxia on pancreatic cancer cells has been
modeled extensively in vitro. For instance, cell lines
surviving hypoxia show enhanced invasive and migratory
propensities,56,57 indicating that this condition favors cancer
progression. Although the precise mechanisms by which
hypoxia affects this process remain incompletely understood,
changes in oxygen tension switch metabolism, modulate
autophagy-mediated survival and death, modulate genomic
instability, and promote additional cell responses that further
facilitate malignant clonal selection.Mechanistically, oxygen
deprivation triggers the stabilization of hypoxia-inducible
factor 1a (HIF-1a), which dimerizes with HIF-1b, under-
goes nuclear translocation, and binds to a multitude of
hypoxia-responsive elements present in the cancer genome.
These events activate a complex geneticeepigenetic program
that seeks to counteract the deleterious impact of decreased
oxygen tension.58 HIF-1a is overexpressed in PDAC,59
where it regulates gene networks involved in autophagy,
glycolysis, angiogenesis, epithelial-to-mesenchymal transi-
tion, and metastasis.58,60 This is a good example of how
transcription and chromatin-induced changes in gene
expression contribute to pancreatic carcinogenesis. Another
example is revealed by studies on the small chromatin
binding protein, nuclear protein 1. Nuclear protein 1 is
overexpressed in PDAC,61,62 where it is induced by hypoxia,
glucose deprivation, and other stresses.63,64 Genetic inacti-
vation of nuclear protein 1 sensitizes PDAC cells to hypoxia
and nutrient deprivation and induces their death byajp.amjpathol.org - The American Journal of Pathology
Abnormal Histogenesisautophagy.64 In this manner, nuclear protein 1 works as
a sensor of tumor cell stresses that, when activated, protects
tumor cells against damage caused by a hostile environment.
Thus, in summary, PDAC cells become primed for survival
under hypoxic environments by deploying a deﬁned gene
expression network, which ultimately results in a more
resistant phenotype, illustrating another positive feedback
loop that drives PDAC progression.A Metabolic Switch Is a Deﬁning Feature of
Highly Aggressive Pancreatic Cancer
Hypoxia not only affects epithelial cells, but also stimulates
the activation of mesenchymal cells that secrete angiogenic
factors such as vascular endothelial growth factor in an
attempt to increase O2 through enhanced vascular perme-
ability and angiogenesis.65,66 Despite this mechanism,
PDAC still fails to increase its vascularity as robustly as
other tumors, suggesting that the function of proangiogenic
factors is counterbalanced by antiangiogenic molecules such
as endostatin.65 Thus, both angiogenic and antiangiogenic
substances secreted in different amounts at various times
during the development of pancreatic cancer ultimately lead
to a functional equilibrium characterized by the hypo-
vascularity that is typical of this malignancy.
One of the major consequences of intratumoral hypoxia is
the metabolic switch from the primary use of oxidative
phosphorylation to reliance on the glycolysis that occurs to
meet the requirements of tumor proliferation under low
oxygen and low nutrient supply.67 Although normal cells rely
primarily (90%) on oxidative phosphorylation, approximately
50% of cellular energy is produced by glycolysis in tumor
cells, with the remainder being generated in the mitochondria,
even in the presence of ample oxygen to fuel mitochondrial
respiration, a phenomenon known as the Warburg effect.68
This metabolic transformation is a consequence of acquired
mutations that lead to cancer, coupled with hypoxic and
nutrient-deﬁcient conditions and faulty architectural relation-
ships among cells and vessels, all of which contribute to the
selection of tumor clones able to survive this hostile envi-
ronment. Congruently, PDAC tumors in vivo show alterations
in pathways involved in thismetabolic switch,69which even at
the PanIN2 and 3 stages lead to increased expression of the
glucose transporter 1 (GLUT1), a protein that is critical for
glucose uptake by tumor cells.70 Subsequently, hypoxia also
functions as a key mechanism that increases glycolysis. For
example, thehypoxia-induced stabilization ofHIF-1a not only
regulates angiogenesis, but also directly up-regulates several
genes involved in this process, such as GLUT1, hexokinase 1
and 2, lactate dehydrogenase A, and lactate transporter mon-
ocarboxylate transporter 4.71
Deﬁned genetic alterations, such as loss of p53 function,
also stimulate glycolysis at several levels.71 Similarly, acti-
vation of Ras inhibits pyruvate kinase and stimulates GLUT1
translocation to the plasma membrane.71 Consequently,The American Journal of Pathology - ajp.amjpathol.orgturning off the expression of an inducible KrasG12D oncogene
in PDAC cells leads to reduced glucose uptake, decreased
expression of rate-limiting glycolytic enzymes, decreased
lactate production, and reduced channeling of glucose
metabolites into nonoxidative anabolic pathways such as
hexosamine biosynthesis.72 These changes in metabolic
programming by KrasG12D are mediated, at least in part, by
mitogen-activated kinases and Myc.72 Therefore, shifting
substrates from energy production to molecular synthesis
seems to provide tumor cells with advantages that help to
account for its increased survival and aggressiveness.
Glycolytic pathways produce ATP and pyruvate that
generate bioproducts, which enter the pentose phosphate
pathway to generate ribose-5-phosphate and NADPH, key
intermediates in nucleotide biosynthesis. During glycolysis,
conversion of glucose to fructose provides an essential
substrate for the nonoxidative pentose phosphate pathway.
Pyruvate, another major intermediate, is converted to lactate
by lactate dehydrogenase and secreted into the extracellular
environment. Lactate secreted by tumor cells could be
absorbed by stromal cells and converted to pyruvate that is
used either for oxidative phosphorylation or secreted again
and then taken up by tumor cells for use as glycolytic fuel.71,73
A recent study investigated the expression of glycolytic
proteins in PDAC tumors and associated stromal cells to show
that both primary PDAC tumors and metastases express high
levels of proteins involved in glycolysis (eg, GLUT1 and
hexokinase 2) compared with normal tissue.69 GLUT1 also
is increased in tumor-associated stromal cells, although
to a lesser degree than in the tumor cells.69 In totality, the
epithelial cell and tumor microenvironment relationship not
only regulates morphogenesis by paracrine/autocrine mech-
anisms and drives angiogenesis, but also actively participates
in the recycling of metabolites within the tumor. This recy-
cling of metabolites, as in the case of the lactate cycle, is
critical tomaintain the energetic needs of the tumor, leading to
the prediction that a better understanding of these interactions
between cancer cells and the surrounding populations can be
exploited for diagnostic (eg, labeled metabolites) or thera-
peutic efforts (eg, metabolic manipulations).Conclusions
The particularly bad prognosis that is observed for patients
with PDAC is at least in part owing to the pancreatic trans-
formed cells that develop in cooperation with surrounding
stromal cells. Activated PSCs and immune cells may be
recruited in response to pancreatic injury and/or mutant
epithelial cells, and initially may provide growth factors and
cytokines that nurture preneoplastic epithelial cells, selecting
for clones with key mutations, such as KRAS. Because PSCs
proliferate and secrete ECM proteins, an adverse desmo-
plastic microenvironment is formed, characterized by
hypoxia and nutrient starvation as a consequence of its
hypovascularization, which selects for aggressively invasive,1083
Iovanna et alchemotherapy-resistant tumor cells. Hypovascularization-
induced hypoxia activates HIF-1a accumulation in tumor
cells, which together with Kras activation increases auto-
phagy and induces a metabolic switch to glycolysis. The low
vascularization of tumors also impedes the delivery of
chemotherapeutic drugs. On the other hand, the presence of
high intratumoral concentrations of antiapoptotic cytokines
also enhances tumor cell survival. Tumor cells show some
characteristics of embryonic cells and, through interactions
with stromal cells, participate in a warped recapitulation of
tissue morphogenesis. Together, these ﬁndings suggest that
the development of therapeutic approaches that target stromal
cells, stromal/tumor communication, hypoxia, and/or glyco-
lytic metabolism may bring novel treatments for PDAC.References
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